The direct renin inhibitor aliskiren improves vascular remodelling in transgenic rats harbouring human renin and angiotensinogen genes

We tested the hypothesis that chronic treatment with the direct rennin inhibitor aliskiren improves the remodeling of resistance arteries in double transgenic rats (dTGR). dTGR (5 weeks) were treated with aliskiren (3 mg/kg/day) or ramipril (1 mg/kg/day) for 14 days and compared with age-matched vehicle-treated dTGR. Blood pressure was similarly reduced in both aliskiren-treated and ramipril-treated rats compared to control dTGR (167±1 mmHg and 169±2 mmHg vs 197+/-4vmmHg, respectively P<0.05). Media-to-lumen ratio assessed on pressurized preparations was equally reduced in aliskiren-treated and ramipril-treated rats compared to controls (6.3+/-0.5 % and 6.4+/-0.2 % vs 9.8+/-0.4%, respectively; P<0.05). Endothelium-dependent and -independent relaxations were similar among the groups. L-NAME significantly reduced acetylcholine-induced dilation in drug-treated dTGR. This effect was significantly more prominent in aliskiren treated rats. eNOS expression showed a 2-fold increase only in aliskiren-treated dTGR as compared to controls (P<0.01) and ramipril-treated dTGR (p<0.05). Plasma nitrite, as an index of NO production, was significantly increased in dTGR treated with either aliskiren or ramipril compared to controls. Only aliskiren induced a 2-fold increase of plasma nitrite, which was significantly greater than that induced by ramipril (P